Temodal (temozolomide) - risk of liver problems - for health professionals

Merck Canada Inc., in consultation with Health Canada, would like to inform you of new warnings for TEMODAL® (temozolomide) regarding cases of hepatic injury, including fatal hepatic failure reported post-marketing. TEMODAL® is an antineoplastic agent indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. It is also indicated for treatment of adult patients with glioblastoma multiforme or anaplastic astrocytoma and documented evidence of recurrence or progression after standard therapy. Read more here.